Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI Sequencing study
NCT00384592Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esomeprazole in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Primary endpoint: Change in frequency of heartburn at 8 weeks. Started Sep 2006; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00384592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384592.